Cyclopharm Limited (ASX: CYC) is pleased to provide the following update on its business and financial performance for FY2020, including progress towards gaining United States Food and Drug Administration (“USFDA”) approval to distribute Technegas in the USA in 2021.
For more information, download the attached PDF.
Download this document
